A Glance at the Cost of Chelation Therapy with Desferal and Exjade in Iran
Journal Title: Iranian Journal of Blood and Cancer - Year 2010, Vol 3, Issue 1
Abstract
Background: Thalassemia is a series of hemoglobinopathies in which the production of perfect hemoglobin is completely or partially suppressed. Using injectable iron chelators have been dominating treatment for the iron overload caused by recurrent blood transfusions in thalassemic patients, however, a new oral iron chelating drug (Exjade) have been recently introduced and might be cost effective compared to previous treatment methods. This study was undertaken to evaluate the cost of Exjade in comparison with injectable iron chelators. Patients and Methods: In this retrospective study, we calculated the cost of iron chelation with Deferoxamine mesylate or Desferal in three groups of patients including those with optimum moderate and poor compliance. Afterwards, we compared the cost with the cost of iron chelation using Exjade. The cost of drugs and treatment for complications caused by iron overload were both taken into account. Results: The average cost of treatment per year with Deferoxamine mesylate was 85601032 Rials for patients with poor compliance, 62739714 Rials for patients with moderate compliance, and 50118376 Rials for patients with optimum compliance. In addition, according to the latest price of Exjade in Iranian market, we found out a regular oral iron chelation therapy using Exjade, with a dose of 20 mg/kg, to cost 76650000 Rials per year. Conclusion: Our findings indicate that using Exjade is cost-effective for those patients who have poor compliance to parenteral treatment. More investigations should be implemented to find the social and economic impact of Exjade therapy on quality of life among patients needing iron chelation therapy.
Authors and Affiliations
M. Hadipour Dehshsal, MR. Shah Ahmad Ghasemi
Keywords
Related Articles
- EP ID EP373444
- DOI -
- Views 131
- Downloads 0
Medium and High-Dose Methotrexate-Induced Toxicity in Children with Acute Lymphoblastic Leukemia
Background: Methotrexate has an important role in treatment of acute leukemia. We measured methotrexate level in CSF and blood of children with acute lymphoblastic leukemia to determine complications and outcomes. Materi...
Allele Frequencies of HLA-A, B and DRB1 among People of Fars Ethnicity Living in Tehran
Background: Human leukocyte antigens (HLA) are polymorphic cell surface proteins. Distribution of HLA alleles vary among different racial and ethnic populations in unrelated stem cell registries. Determination of HLA all...
The Survey of Effective Agents on Factor VIII and IX Inhibitors in Patients with Hemophilia A and B in Kermanshah Province
Background: Hemophilia is the most frequent severe hereditary hemorrhagic disease due to deficiency of coagulation factors VIII (Hemophilia A) or IX (Hemophilia B) in plasma. We aimed to identify patients with hemophili...
Association between Red Cell Distribution Width and Mortality in Pediatric Patients Admitted to Intensive Care Units
Background: Red cell distribution width (RDW) is a routine laboratory measure that could be used as a predictor of mortality in critically ill patients. Identification of patients at risk for mortality early in the cours...
Frequency of Human Platelet Antigens (HPA-2/3/5) Polymorphism in Iranians Evaluated by RFLP-PCR
Background: Knowing the human platelet antigens (HPA) and genes frequency in different populations is important not only for population studies but also for clinical transfusion practice. HPA genes frequency in Iran is n...